SVG
Diversity in Clinical Trials
Overview
The underrepresentation of diverse groups in clinical research, mistrust in research, and the lack of diversity in the health workforce play significant roles in the persistence of health inequities. FasterCures aims to develop strategies and policies to increase diversity and inclusion in all stages of clinical research and to change the culture of systems within the biomedical research community to value diversity and representation in the development and execution of clinical trials.
Diversity in Clinical Trials
Featured Thought Leadership
Milken Institute Statement on Newly Released FDA Guidance on Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Trials
The Milken Institute celebrates the publication of the second iteration of the Food and Drug Administration (FDA) draft guidance on Diversity Action Plans (DAP) to improve clinical trial diversity by enrolling underrepresented populations...Read Statement
Patients Most In Need Face Obstacles to Participating in Life-Saving Clinical Trials According to a New Milken Institute Report
June 24, 2024 (Washington, DC)— Clinical trials can provide the possibility to obtain novel treatments for conditions and diseases that are not yet commercially available. Yet, these lifesaving treatments are often difficult or impossible...Read ArticleImage
Paul Guequierre
Director, Strategic CommunicationsPaul Guequierre is the director of strategic communications. In this role, he works to increase the profile of Milken Institute in the media, raise the visibility of issues important to the organization and its stakeholders, and expand the Institute's digital presence.
Toward a National Action Plan for Achieving Diversity in Clinical Trials
This report details the actions organizations and sectors from across the enterprise can take to create a clinical trials enterprise that is diverse, equitable, inclusive, and accessible to all.Read Report
BM
MH
SO
WD
Race and Ethnicity Data Collection in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products
Lauren K. Roth Associate Commissioner for Policy Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Dear Ms. Roth, FasterCures is pleased to respond to the Request for Comments on the FDA Draft Guidance for the...Read LetterImage
Yasmeen Long
Director, FasterCuresYasmeen Long is a director with the FasterCures team of MI Health. Her expertise lies within health equity, disparities, outcomes, policy, clinical research, patient engagement, and social determinants of health.
Demographic Reporting and Mix in Clinical Trials
Clinical trial enrollment can vary based on demographics. Cancer drug trials, for example, have been shown to skew disproportionately toward young, White, male participants. Variability also exists in a treatment’s effectiveness across...Read Report
Advancing Clinical and Translational Science Through Accelerating the Decentralization of Clinical Trials
Submitted electronically Joni Rutter, Ph.D. National Center for Advancing Translational Sciences National Institutes of Health 6701 Democracy Blvd Bethesda, MD 20892-4874 Dear Director Rutter, FasterCures, a center of the Milken Institute...Read LetterImage
Esther Krofah
Executive Vice President, Milken Institute HealthEsther Krofah is the executive vice president of Milken Institute Health, leading FasterCures, Public Health, the Future of Aging, and Feeding Change. She has extensive experience managing efforts to unite diverse stakeholders to solve critical issues and achieve shared goals that improve patients’ lives.End of Year Legislative Package – Health Provisions
Submitted electronically The Honorable Patty Murray Chair Committee on Health, Education, Labor, and Pensions United States Senate Washington, DC 20510 The Honorable Richard Burr Ranking Member Committee on Health, Education, Labor, and...Read LetterImageEsther Krofah
Executive Vice President, Milken Institute HealthEsther Krofah is the executive vice president of Milken Institute Health, leading FasterCures, Public Health, the Future of Aging, and Feeding Change. She has extensive experience managing efforts to unite diverse stakeholders to solve critical issues and achieve shared goals that improve patients’ lives.
Increasing Diversity in Clinical Trials to Reduce Health Disparities
In an incredibly diverse world, health inequities and resulting disparities continue to stand out as a persistent yet addressable challenge. As the global biopharmaceutical industry works to treat, prevent, or even cure diseases, we have a...Read Essay
A Call to Action for Diversity in Clinical Trials
FasterCures has initiated a body of work to advance system change within biomedical research to focus on and value diversity and representation within clinical trials. Following our report, ' Achieving Health Equity: A Multi-Stakeholder...Read Brief
JM
Health Economics Driving New Investments
Panelists first explore the economic and financial toll of health inequities in hindering access to affordable health care, including drugs and treatments as well as participation in clinical trials. Conversely, they review measures that policymakers and industry—particularly within the C-suite—can take to effect meaningful change in making the health-care and research ecosystem more equitable and affordable.
Related Videos
Digital Health Equity and Technology: Where Are We Now?Research has shown that racial biases can be built into medical products, leading to misdiagnoses, inaccurate readings, and delays in therapy.
Building and Sustaining Diversity & Equity in Digital Health WorkshopDuring the workshop, experts discussed prevailing barriers to representation and inclusion and efforts to improve equity in digital health technologies.
Building a Diverse and Equitable Health Workforce to Increase Trust in Medical Research and HealthcareTo promote health equity within the biomedical research and health-care systems, we must focus on having a culturally competent and diverse workforce.
Improving Health Equity in Rare Diseases ResearchPeople with rare diseases face many barriers and inequities in accessing diagnosis, treatment, and comprehensive care. This burden is even greater among marginalized communities with rare diseases.
How Can We Ensure Access to Health Innovation for All?Innovation means nothing without access, and barriers to access for many patients—particularly for communities already underserved and lacking access to high-quality care—are real.
The New ROI: Advancing an Equitable and Inclusive Biomedical Research EcosystemAs a result of the COVID-19 pandemic, systemic health-care inequities persist along with public skepticism and mistrust in the system.
A Conversation with Marcella Nunez-Smith on COVID-19 and Health EquityA Conversation with Marcella Nunez-Smith on COVID-19 and Health Equity
The Impact of Investing in Health Equity in Biomedical ResearchBiomedical research relies on commercial investment, grant funding, and private donations to accelerate drug development, run clinical trials, and support innovation in health technologies.